CIK 0001907108
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Lexeo Therapeutics, Inc.
Sign in to watch- Ticker
- LXEO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 854012572
- Phone
- +1 212-547-9879
- Business address
- 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010
- 4 Open-market sale Chief Medical Officer sold 585 shares at $2.77 ($1,623)
- 4 Open-market sale Chief Legal Officer sold 521 shares at $2.77 ($1,445)
- 4 Open-market sale Chief Development Officer sold 367 shares at $2.77 ($1,018)
- 4 Grant or award Chief Technical Officer acquired 5,720 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 5,720 shares (grant or award)
- 4 Grant or award Chief Development Officer acquired 5,720 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 2,128 shares (grant or award)
- 4 Open-market sale Chief Executive Officer sold 4,326 shares at $4.41 ($19,091)
- 4 Open-market sale Chief Development Officer sold 1,486 shares at $4.41 ($6,558)
- 4 Open-market sale Chief Medical Officer sold 2,359 shares at $4.41 ($10,410)
- 4 Open-market sale Chief Legal Officer sold 2,101 shares at $4.41 ($9,272)
- 4 Grant or award Chief Financial Officer acquired 40,875 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 103,750 shares (grant or award)
- 4 Grant or award Chief Technical Officer acquired 26,250 shares (grant or award)
- 4 Grant or award Chief Legal & Admin Officer acquired 36,250 shares (grant or award)
- 4 Grant or award Chief Development Officer acquired 38,750 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 43,750 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Chief Executive Officer sold 2,500 shares at $8.20 ($20,491)
- 4 Open-market buy Director bought 15,000 shares at $6.99 ($104,852)
Page 4 of 7 · 121 filings